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Abstract: Achromobacter species have attracted attention as emerging pathogens in cystic fibrosis.
The clinical significance of Achromobacter infection is not yet fully elucidated; however, their intrinsic
resistance to antimicrobials and ability to form biofilms renders them capable of establishing long-term
chronic infections. Still, many aspects of Achromobacter biofilm formation remain uncharacterized.
In this study, we characterized biofilm formation in clinical isolates of Achromobacter and investigated
the effect of challenging the biofilm with antimicrobials and/or enzymes targeting the extracellular
matrix. In vitro biofilm growth and subsequent visualization by confocal microscopy revealed
distinctly different biofilm morphotypes: a surface-attached biofilm morphotype of small aggregates
and an unattached biofilm morphotype of large suspended aggregates. Aggregates consistent
with our in vitro findings were visualized in sputum samples from cystic fibrosis patients using
an Achromobacter specific peptide nucleic acid fluorescence in situ hybridization (PNA-FISH) probe,
confirming the presence of Achromobacter biofilms in the CF lung. High antibiotic tolerance was
associated with the biofilm phenotype, and biocidal antibiotic concentrations were up to 1000 fold
higher than for planktonic cultures. Treatment with DNase or subtilisin partially dispersed the
biofilm and reduced the tolerance to specific antimicrobials, paving the way for further research into
using dispersal mechanisms to improve treatment strategies.
Keywords: Achromobacter; cystic fibrosis; biofilm; biofilm morphology; dispersal; confocal microscopy;
PNA-FISH; antimicrobial susceptibility testing
PACS: J0101
1. Introduction
Cystic fibrosis (CF) is an inherited chronic disease characterized by the development of chronic
pulmonary infections caused by increased viscosity of bronchial mucus and impaired mucocilliary
clearance of inhaled bacteria [1–3]. Achromobacter sp. are increasingly isolated from cystic fibrosis
patients. Although the increased prevalence has partially been ascribed to improved identification
techniques and increased attention to the identification of Achromobacter species, other important factors
such as aggressive antimicrobial treatment and prolonged lifespan of the patients may also have given
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rise to increased prevalence rates. As well as being innately resistant to many antimicrobial agents,
Achromobacter may also develop resistance to virtually all available antibiotics [4–7], and have attracted
attention as emerging pathogens in cystic fibrosis [8]. Several species within the genus Achromobacter
have been isolated from cystic fibrosis patients; the most common being Achromobacter xylosoxidans
however, other Achromobacter species may also cause infections in these patients [9,10].
A. xylosoxidans has the capacity to form biofilm [11,12], and biofilm formation is a key aspect of
the chronic lung infections of cystic fibrosis patients. Biofilms are diverse structures with variable
morphology, growing either attached to a surface or as unattached aggregates [13,14]. In a biofilm,
bacterial cells aggregate into micro colonies embedded in a matrix of extracellular polymeric substances
(EPS). The components and the amount of EPS often vary depending on the bacterial species,
the environmental conditions, and the maturation stage of the biofilm [15].
The matrix provides a protective environment, shielding bacteria against antimicrobials and host
defense systems [16,17]. Furthermore, bacteria commonly reduce their metabolic activity when in
a biofilm, a trait further enhancing their antimicrobial tolerance [18]. Taken together, these factors lead
to difficulties when treating cystic fibrosis patients, rendering biofilm infections in the lungs of these
patients hard if not impossible to eradicate, thus leading to chronic pulmonary infections; the main
cause of morbidity and mortality in cystic fibrosis patients. The clinical impact of Achromobacter
biofilm formation is still unclear, and the literature regarding Achromobacter largely consists of case
reports while only few studies regarding Achromobacter in vitro biofilm formation and antimicrobial
susceptibility have been published [11,19]. Many aspects of Achromobacter biofilm formation thus
remain to be investigated. Eradication of biofilm infections often fail despite aggressive antimicrobial
treatment. A better understanding of the capacity of Achromobacter to form biofilm may help
improve diagnosis and treatment strategies of Achromobacter in cystic fibrosis patients. In this study,
we investigated biofilm formation in clinical isolates of Achromobacter obtained from chronically
infected cystic fibrosis patients. The aim was to gain further insight into fundamental aspects of the
biofilm morphology and composition of clinical Achromobacter isolates, and to investigate the effect of
challenging the biofilm with antimicrobials and/or enzymes targeting the extracellular matrix.
2. Materials and Methods
2.1. Bacterial Strains
Isolates of the clinical Achromobacter strains used in this study were obtained from airway
secretions collected from cystic fibrosis patients during routine investigation at the CF center at
Aarhus University Hospital, Denmark. Identification to species level of the strains used in this
study had previously been performed using Multilocus Sequence analysis (MLSA) [20,21]. Biofilm
formation was investigated for 23 Achromobacter isolates and one isolate of P. aeruginosa PAO1 DSMZ
19880 (Table 1). Three Achromobacter isolates were obtained from culture collections; two type
strains (A. xylosoxidans LMG 1863 and A. ruhlandii CCUG 38886), and one environmental isolate
(A. xylosoxidans CCUG 14603). Fifteen of the 20 clinical Achromobacter isolates originated from five
CF patients [21], with three isolates from each: One isolate “a” was a first time isolate obtained the
first time an Achromobacter was cultured from a routine sputum sample. Isolate “b” was selected
approximately one year after the patient was first infected, and the third isolate “c” was selected
approximately four years after the patient was first infected with Achromobacter. The “b” and “c”
isolates are henceforth referred to as “later” isolates. The isolates were identified as A. ruhlandii (CF1),
A. xylosoxidans (CF2) and A. insuavis (CF3-CF5). Five additional isolates originated from five different
patients; three isolates of A. xylosoxidans (CF6-CF8) and two isolates of A. ruhlandii (CF9 and CF10).
Pulsed-field gel electrophoresis typing of isolates showed that CF9 and CF10 both belonged to the
same clone, the Danish Epidemic Strain (DES) of A. ruhlandii [22,23], and thus represented putative
cases of patient-to-patient transmission. All other isolates were unique (S. Gade, N. Nørskov-Lauritsen
and W. Ridderberg, submitted for publication). Isolates were cultured on 5% blood agar at 37 ◦C.
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Planktonic cultures were obtained by inoculating sterile media (Brain Heart Infusion (BHI) broth
(Fluka) or ABT minimal medium containing 0.5% glucose) with a single colony and incubating at
37 ◦C overnight in Erlenmeyer flasks with shaking at 180 rpm. Prior to each experiment, overnight
cultures were adjusted to OD600 of 0.1 using fresh growth media, corresponding to approximately
106 CFU/mL.
Table 1. Bacterial strains used in this study.
Species Isolate Strain Identification Origin Source
A. xylosoxidans Type strain LMG 1863T Osaka, Japan Ear
A. ruhlandii Type strain CCUG 38886T Soil
P. aeruginosa PAO1 DSMZ 19880
A. xylosoxidans Environmental isolate CCUG 14603 Lyon, France Water
A. ruhlandii CF1-a J9557-07 Aarhus, Denmark CF clinical isolate
A. ruhlandii CF1-b J4616-09 Aarhus, Denmark CF clinical isolate
A. ruhlandii CF1-c J4951-12 Aarhus, Denmark CF clinical isolate
A. xylosoxidans CF2-a J19840-07 Aarhus, Denmark CF clinical isolate
A. xylosoxidans CF2-b J19373-08 Aarhus, Denmark CF clinical isolate
A. xylosoxidans CF2-c J8663-11 Aarhus, Denmark CF clinical isolate
A. insuavis CF3-a J10719-08 Aarhus, Denmark CF clinical isolate
A. insuavis CF3-b J13140-09 Aarhus, Denmark CF clinical isolate
A. insuavis CF3-c J13665-10 Aarhus, Denmark CF clinical isolate
A. insuavis CF4-a J14174-08 Aarhus, Denmark CF clinical isolate
A. insuavis CF4-b J10317-09 Aarhus, Denmark CF clinical isolate
A. insuavis CF4-c J1036-12 Aarhus, Denmark CF clinical isolate
A. insuavis CF5-a J15059-09 Aarhus, Denmark CF clinical isolate
A. insuavis CF5-b J23156-10 Aarhus, Denmark CF clinical isolate
A. insuavis CF5-c J5762-12 Aarhus, Denmark CF clinical isolate
A. xylosoxidans CF6 J20454-08 Aarhus, Denmark CF clinical isolate
A. xylosoxidans CF7 J15887-08 Aarhus, Denmark CF clinical isolate
A. xylosoxidans CF8 J15976-09 Aarhus, Denmark CF clinical isolate
A. ruhlandii CF9 J18469-02 Aarhus, Denmark CF clinical isolate
A. ruhlandii CF10 J10633-12 Aarhus, Denmark CF clinical isolate
2.2. Fast Screening of Biofilm Formation
All strains were subjected to quantification of biofilm formation using a crystal violet micro
titer assay, modified and adapted for adherence to peg-lid (Nunc-immuno™ TSP) [24,25]. In brief,
overnight cultures were adjusted to OD600 = 0.1 with fresh BHI, and 160 µL per well was added to
96 well micro titer plates (Nunc, Nunclon Delta Surface, Thermo Fischer Scientific, Waltham, MA, USA).
Peg-lids were inserted and plates were incubated statically for 24 h at 37 ◦C. Following incubation,
the peg-lids were gently immersed in water to remove unbound bacteria and inserted into 96 well
plates containing 180 µL 1% crystal violet solution in water and incubated for 15 min to stain the
biofilm adhering to the pegs. The pegs were then washed three times by gently immersing them in
water to wash off unbound crystal violet and left to air-dry for 20 min. Crystal violet was extracted
by submerging the pegs in 96% ethanol (180 µL in each well) for 15 min, and the amount of biofilm
was determined by optical density measurements of crystal violet at 585 nm using a BioTek Power
wave XS2 plate reader (Holm & Halby, Brøndby, Danmark). The experiment was carried out with
three biological and eight technical replicates. The result of this screening procedure was used to select
strains for further characterization.
Growth rates of individual strains were determined by optical density measurements at 600 nm
during growth of planktonic cultures in BHI in 96 well plates with 200 µL in each well. The bacteria
were grown at 37 ◦C with shaking. Measurements were taken every 30 min using a Multiskan™ GO
Microplate Spectrophotometer (Thermo Fisher Scientific) in kinetic mode.
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2.3. Characterisation of Biofilms Grown under Continuous Flow
For characterization of structure and matrix composition, biofilms of A. xylosoxidans LMG 1863T,
A. xylosoxidans CF2-b and A. insuavis CF4-b were grown under continuous flow as described [26].
Briefly, planktonic cultures of each strain were grown overnight in ABT media. One mL was injected
into a flow chamber (µ-Slide VI 0.4, ibidi GmbH, Martinsried, Germany) connected to a peristaltic
pump. The cells were left to attach for 11/2 h without flow. Biofilms were cultured for 48 h at 37 ◦C
during continuous flow in ABT media with a flow rate of 1.5 mL/h. The biofilms were stained
by injecting stains into the flow chamber. LIVE/DEAD® stain (BacLight L7007 bacterial viability
kit for microscopy, Invitrogen, Thermo Fisher, Waltham, MA USA) was prepared according to the
manufacturer’s protocol, with the modification that the concentration of propidium iodide was
increased to 0.05 mM, in order to stain extracellular DNA [27]. Three µL LIVE/DEAD® stain diluted in
1 mL 0.85% NaCl was injected into the flow chamber. The biofilm was stained for 15 min. Thereafter, the
biofilm was stained with Calcofluor (100 mg/mL in 0.85% NaCl) (Sigma-Aldrich, St. Louis MO, USA)
for fifteen min and rinsed with 0.85% NaCl for fifteen min at continuous flow prior to imaging using
confocal laser scanning microscopy (CLSM) (Zeiss LSM 700, Carl Zeiss AG, Oberkochen, Germany).
2.4. Characterisation of Statically Grown Biofilms
A. insuavis CF4-b did not produce an attached biofilm and could therefore not be studied under
flow. To characterize the structure and matrix composition of unattached biofilm, A. insuavis CF4-b
was grown in planktonic culture overnight in ABT media. A microscopy dish (µ-Dish 35 mm, high,
ibidi GmbH, Martinsried, Germany) was inoculated with two mL planktonic and incubated for 48 h
at 37 ◦C. Following incubation, growth media was carefully removed paying close attention to not
disturbing the aggregated structures. The microscopy dish was gently rinsed twice with two mL PBS
to remove planktonic bacteria. Biofilm aggregates were stained for 15 min by carefully adding one
mL LIVE/DEAD® stain as described above. The biofilm was then stained with Calcofluor for 15 min,
and rinsed three times with one mL 0.85% NaCl. Finally, two mL of an 80% glycerol solution was
added to stabilize the biofilm prior to imaging using confocal microscopy.
2.5. Detection of Achromobacter Aggregates in Sputum Samples from Cystic Fibrosis Patients Using Peptide
Nucleic Acid (PNA) Fluorescent in Situ Hybridization (FISH)
PNA-FISH was performed on sputum samples to evaluate the presence and mode of growth of
Achromobacter in order to compare with in vitro biofilm formation. The sputum samples were obtained
from the two CF patients colonized with A. xylosoxidans CF2 and A. insuavis CF4, following routine
examination. Achromobacter specific FISH probe Ach-221 [28] was modified to PNA-FISH (5’-CGC TCY
AAT AGT GCA AGG TC-3’ labeled with Cy3), by Eurogentec (EGT North America, oligonucleotides,
Campus Drive, Freemont, CA, USA).
2.6. Probe Validation on Pure Cultures
The specificity of the Achromobacter PNA-FISH probe was validated against a negative control
strain with two nucleotide mismatches (Neisseria polysaccharea DSM 22809), and P. aeruginosa PAO1 with
A. xylosoxidans CF2-b serving as positive control (Table 1) using seven different hybridization buffers
with increasing formamide concentration (0%, 5% 10% 15% 20% 25% or 30% (vol/vol) formamide).
Hybridization buffer contained 10% (wt/vol) dextran sulphate, 10 mM NaCl, 0.1% (wt/vol) sodium
pyrophosphate 0.2% (wt/vol) polyvinylpyrrolidone, 0.2% (wt/vol) ficoll, 5 mM disodium EDTA,
0.1% (vol/vol) Triton X-100, 50 mM Tris-HCl (all from Sigma-Aldrich), and the selected formamide
concentration [29]. The bacteria were fixed in 4% paraformaldehyde solution in PBS. Ten µL were
added to each well on a microscope slide with six reaction wells (Marienfeld-Superior laboratory
glassware) and air-dried at 37 ◦C. Samples were dehydrated by sequentially submersion in 50%
ethanol, 80% ethanol and 96% ethanol, three minutes in each. Seven µL of hybridization buffer was
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added to each reaction well and 1 µL PNA-FISH probe was mixed with the hybridization buffer to
a final probe concentration of 0.5 µM. The samples were incubated in a moist chamber at 55 ◦C for
90 min in the dark. Thereafter, the samples were washed in pre-heated wash solution (5 mM Tris base,
15 mM NaCl and 1% (vol/vol) Triton X-100 (Sigma-Aldrich) for 30 min at 55 ◦C, dipped once in cold
milliQ water and air dried. Imaging was performed using confocal microscopy using the same settings
for all images and the signal intensity of individual bacterial cells was measured using ImageJ [30].
The best condition for both sensitivity and specificity was achieved at 25% formamide.
2.7. Detection and Distribution of Achromobacter in Sputum Samples Obtained from CF Patients
Sputum samples were fixed with 4% paraformaldehyde solution, embedded in paraffin and
sectioned to a thickness of 4–10 µm. Sections were mounted on microscope slides for confocal
microscopy, dried for two hours at 60 ◦C and stored at −20 ◦C prior to analysis. Samples were
investigated as previously described [31] with minor modifications. In brief, paraffin was removed
by immersing the sample sequentially in xylene (2 × 5 min), 99% ethanol (2 × 3 min), 96% ethanol
(2 × 3 min) and water (3 × 3 min). Samples were air-dried and stored at room temperature prior
to analysis. Fourteen µL hybridization buffer (25% formamide) and two µL probe was added to the
tissue samples to a final probe concentration of 0.5 µM. A cover slip was placed on top of each sample
and samples were incubated in a moist chamber at 55 ◦C for 90 min in the dark. The cover slip was
carefully removed and the samples were washed in pre-heated wash solution for 30 min at 55 ◦C.
Samples were dipped once in cold water and air dried, followed by counter staining with Syto 41
(10 µM in water, Sigma). Imaging was performed by confocal microscopy in λ mode, using a reference
spectrum obtained from pure cultures of Achromobacter hybridized with the Achromobacter specific
PNA-FISH probe and stained with Syto 41.
2.8. Enzyme Treatment to Prevent Biofilm Formation
Overnight cultures were grown in BHI and adjusted to OD600 = 0.1 with fresh BHI, and 160 µL per
well was added to 96 well micro titer plates One of the following enzymes was added before peg-lids
were inserted: DNase I (Deoxyribonuclease I from bovine pancreas, 2297 Kunits/g), alginate lyase
(alginate lyase from Sphingobacterium multivorum, 10.000 U/g) or subtilisin (Protease from Bacillus
licheniformis, 9 U/µg). The two concentrations used were 50 µg/mL (low) and 200 µg/mL (high).
After 24 h incubation at 37 ◦C, biofilm formation in the presence of each enzyme was quantified by
crystal violet staining and compared to controls with no addition of enzyme. The experiments were
carried out three times with eight replicates in each experiment.
2.9. Enzyme Treatment of Mature Biofilms
Biofilms were formed on peg-lids as described above, except in the absence of enzymes. After 24 h
incubation, the peg-lid was transferred to a new plate containing sterile BHI media supplemented with
DNaseI, alginate lyase or subtilisin. Each enzyme was administered in two concentrations; 50 µg/mL
(low) and 200 µg/mL (high). The biofilms were treated for two hours at 37 ◦C before quantification
by crystal violet staining. The experiments were carried out three times with eight replicates in
each experiment.
2.10. Antimicrobial Susceptibility Testing
Antimicrobial susceptibility was tested for ceftazidime, colistin, piperacillin/tazobactam and
tobramycin to evaluate the antibiotic tolerance of biofilms compared to planktonic cultures of the
same isolate.
The minimal inhibitory concentration (MIC) was determined using Etest (Biomérieux) according
to the manufacturer’s protocol. The minimal biocidal concentration (MBC) was determined by twofold
serial dilutions ranging from 1024 µg/mL to 1 µg/mL. Overnight cultures in BHI were adjusted to
OD600 = 0.2 with fresh media and 100 µL/well was added to 96 well plates (Nunc, Nunclon Delta
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Surface, Thermo Fischer Scientific, Waltham, MA, USA). Antibiotics were dissolved in sterile growth
media to a concentration twice that of the desired concentration and 100 µL were added to each well
already containing 100 µL bacterial culture, and mixed by pipetting. Antibiotic-free growth controls
and bacteria-free blanks were included on each plate. The plate was incubated statically for 24 h at
37 ◦C and OD600 was measured. From each well with no visual growth, 100 µL was plated on 5%
blood agar and incubated overnight at 37 ◦C. MBC was defined as the concentration of antibiotics that
yielded a reduction in CFU count of ≥99.9%.
Biofilms were formed on peg-lids in BHI media and incubated for 24 h at 37 ◦C and
transferred to a micro titer plate containing sterile BHI media supplemented with ceftazidime, colistin,
piperacillin/tazobactam or tobramycin (Sigma-Aldrich) in twofold serial dilutions ranging from
8192 µg/mL to 128 µg/mL. The effect of enzyme treatment on MBEC was measured by addition of
DNase I (200 µg/mL), alginate lyase (200 µg/mL) or subtilisin (200 µg/mL) to the micro titer plate
supplemented with antimicrobials. After 24 h incubation at 37 ◦C, the peg-lid was gently rinsed in
sterile media and transferred to a new plate containing fresh, sterile media and incubated for 24 h
at 37 ◦C. Following incubation, the optical density OD600 was measured and from wells with no
apparent growth, 100 µL was plated on 5% blood agar and incubated for 24 h at 37 ◦C. The wells with
no growth were used to identify the minimal concentration of antibiotic needed to completely eradicate
the biofilm. The experiments were carried out three times with three replicates in each experiment.
2.11. Statistical Analysis
Statistical analysis was performed using SigmaPlot (Systat Software, San Jose, CA, USA).
Since data was not normally distributed, a Wilcoxon Mann-Whitney rank-sum test was applied
to compare biofilm formation of isolates and to investigate the effect of enzymatic treatment.
A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Clinical Achromobacter Isolates form Biofilm in Vitro
The ability to form biofilm is believed to be of crucial importance for establishing chronic lung
infections in cystic fibrosis patients. We therefore screened a selection of clinical and non-clinical
Achromobacter isolates to evaluate their ability to form biofilm in vitro. We investigated 23 Achromobacter
strains; three from culture collections and twenty clinical isolates from CF patients. A fast screening
using a crystal violet micro titer peg-lid assay shows that all 23 isolates formed biofilm in BHI media
(Figure 1). A. ruhlandii CCUG 38886T (type strain), A. xylosoxidans CCUG 14603 (environmental isolate),
and the clinical isolates A. ruhlandii CF9 and A. insuavis CF5-a displayed a biofilm forming capacity
similar to PAO1, whereas all other isolates produced less biofilm. Our study included three species
of Achromobacter, and the observed variation in biofilm formation could not be ascribed to a specific
species. Three separate isolates were investigated from five patients, and production of attached
biofilm was generally highest pronounced for first-time isolates (Figure 1), the reduction in biofilm
formation for later isolates attained statistical significance for CF5 and CF2 (p > 0.001). Of the clinical
isolates, A. insuavis CF5-a produced the largest amount of attached biofilm, more than five times
that of A. ruhlandii CF1-b which produced the lowest amount of attached biofilm. A. ruhlandii CF9
and A. ruhlandii CF10 both belong to the same strain (DES), but are isolated from different patients.
CF9 represents an early isolate, whereas A. ruhlandii CF10 represents a late isolate. More attached
biofilm is produced by the early isolate, consistent with the findings from CF2 and CF5. A. xylosoxidans
CF6 and CF8 represent early isolates, whereas CF7 represents a late isolate (approximate 6 years after
first acquisition). Production of attached biofilm varied amongst clinical Achromobacter isolates and
did not appear to be species specific, rather strain and even isolate specific.
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produced by A. xylosoxidans CF2-b, eDNA (red) appeared in clumps between bacterial aggregates 
throughout the biofilm (Figure 2B). This was not observed for A. xylosoxidans LMG 1863T, despite the 
otherwise phenotypically similar appearance of the biofilms produced by the two isolates. Staining 
of A. xylosoxidans LMG 1863T and A. xylosoxidans CF2-b aggregates (Figure 2A,B) suggest 
co-localization of syto 9 (living cells) and calcofluor (polysaccharides). This was not observed for A. 
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A. insuavis CF4-b did not form a surface attached biofilm under flow, and only a few layers of cells 
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Figure 1. Mean production of biofilm ± i 23 chromobacter isolates and P. aeruginosa DSMZ 19880
measured by crystal violet staining (strains are list i l ).
The reduction in biofilm formation in isolates was not caused by reduced in vitro growth rates in
later isolates of the same strain, though variation between strains was observed (Figure S1). Two clinical
isolates from chronic infections were chosen for further investigation, namely A. xylosoxidans CF2-b
characterized by high production of attached biofilm and A. insuavis CF4-b characterized by low level
production of attached biofilm.
3.2. Biofilm Structure, Morphology and Extracellular Matrix Composition
A. xylosoxidans CF2-b, A. insuavis CF4-b and the type strain of A. xylosoxidans LMG 1863T,
were grown under continuous flow (Figure 2). A. xylosoxidans LMG 1863T and A. xylosoxidans CF2-b
produced surface-attached biofilms of similar morphology (Figure 2A,B) containing aggregates of
up to 5 µm in diameter within the biofilm measuring up to 20 µm in thickness. In the biofilm
produced by A. xylosoxidans CF2-b, eDNA (red) appeared in clumps between bacterial aggregates
throughout the biofilm (Figure 2B). This was not observed for A. xylosoxidans LMG 1863T, despite the
otherwise phenotypically similar appearance of the biofilms produced by the two isolates. Staining of
A. xyl soxid ns LMG 1863T and A. xylosoxidans CF2-b aggregates (Figure 2A,B) suggest co-localization
of syto 9 (living cells) and calcofluor (polys ccharides). This was not observed for A. insu vis CF4-b
(Figure 2C,D), suggesting st ain-dependent differences in polysacch ride loc lisation. A. insuavis
CF4-b did not form a surf ce attached biofilm und r flow, and only a few layers of cells and
clumps of polysaccha ides (bl e) were o served (Figure 2C). When grown under static conditions,
how ver, A. insuavis CF4-b displayed a loosely attached or unattached biofilm phenotype of suspended
aggregates of up to approximately 80 µm (Figure 2D). The aggregates were encased in an extracellular
matrix of polysaccharides (blue) forming a peripheral shell around the aggregates. This phenomenon
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was not observed with the two A. xylosoxidans isolates (data not shown). Attachment to an abiotic
surface is not necessarily required for Achromobacter biofilm formation, and unattached aggregates
may possibly be an occurring mode of growth in vivo in sputum within the CF lung.
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A. xylosoxidans CF2-b and A. insuavis CF4-b. Biofilms were grown for 48 h at continuous flow (A–C)
and at static conditions (D) and visualized by confocal microscopy. Living cells were stained with
Syto 9 (green), dead cells and extracellular DNA with propidium iodide (red) and polysaccharides
were stained with fluorescent bright ner (b ue). A. xylosoxidans LMG 1863T (A) and A. xylosoxisans
CF2-b (B) produced surface attach biofilm, whereas A. i suavis CF4-b (C) fa led to form biofilm
under continuous fl w, but formed suspended aggregates encased in polysaccharides (blue) when
grown at static conditions (D).
3.3. Visualization of Achromobacter in Sputum Samples from Cystic Fibrosis Patients, Exhibit Resemblance
with Biofilm Aggregat s
Achromobacter has been shown to form biofilm in vitro [11,12], but the mode of growth in vivo
has yet to be fully elucidated. To investigate the formation of in vivo biofilm, sputum samples from
patient CF2 and CF4 were collected in early 2015. Achromobacter-specific PNA-FISH probes was used
to visualize the spatial distribution of these bacteria within the sputum samples. The specificity
of the probe was validated in vitro showing no unspecific binding to the selected control strains
at the formamide concentration used. Achromobacter sp. were grown from both sputum samples
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and aggregates were visualized in the sputum by PNA-FISH (Figure 3). The aggregates were
heterogeneously distributed in the samples and reached a diameter of 5–10 µm for patient CF2 and up
to 40 µm for patient CF4. The aggregate morphology was consistent with our in vitro observations;
however, Achromobacter aggregates visualized in sputum were generally smaller than observed in vitro.
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The aggregates were 5–10 µm in diameter in patient CF2 (A), and up to 40 µm in patient CF4 (B).
The distribution of aggregates was heterogeneous, and the images do not reflect the general abundance
of Achromobacter in the sample.
3.4. Extracellular Matrix Components Are Important for Formation and Stability of Achromobacter Biofilm
The ability of bacteria to form biofilm depends on various factors, amongst which production
of the extracellular matrix is of key importance for the biofilm structure and stability. To examine
the importance of various biomolecules for development and maintenance of biofilm structure and
stability in Achromobacter, we removed extracellular DNA (eDNA), protein or alginate by enzymatic
treatment with DNase, subtilisin, or alginate lyase. The effect of EPS-degrading enzymes on formation
of attached biofilm was investigated by adding the enzymes simultaneous with inoculating bacteria
for biofilm growth (Figure 4a–c). The degradation of alginate by alginate lyase (200 µg/mL) reduced
the amount of attached biofilm produced by A. xylosoxidans CF2-b (41%, p = 0.01) and A. insuavis
CF4-b (34%, p < 0.001), whereas alginate lyase had no effect on the amount of attached biofilm in
A. xylosoxidans LMG 1863T. Degradation of eDNA by DNase I (200 µg/mL) reduced the amount
of attached biofilm produced by all three isolates (A. xylosoxidans LMG 1863T with 38%, p < 0.00;
CF2-b with 53%, p < 0.001 and CF4-b with 48%, p = 0.004) thus having the greatest overall effect
on limiting the formation of attached biofilm. Surprisingly, addition of DNase I at 50 µg/mL
significantly increased, rather than decreased, the amount of attached biofilm formed by A. insuavis
CF4-b (38%, p = 0.001). The addition of 50 µg/mL subtilisin reduced the amount of biofilm formed
by A. xylosoxidans CF2-b (72%, p < 0.001) and A. insuavis CF4-b (48%, p < 0.001), whereas 200 µg/mL
subtilisin increased the amount of biofilm formed by A. xylosoxidans LMG 1863T (67%, p = 0.0154).
To investigate the importance of various biomolecules for maintenance of matured biofilms, we
investigated if 2 h enzyme treatment of 24 h old biofilms would lead to dispersal (Figure 4d–f). DNase I
treatment resulted in a significant reduction in attached biofilm for all isolates (A. xylosoxidans LMG
1863T with 57%, p = 0.0017; A. xylosoxidans CF2-b with 51%, p = 0.0026 and A. insuavis CF4-b with 63%,
p = 0.0015) (Figure 4e). In contrast, treatment with subtilisin showed larger variability between strains,
with a reduction of attached biofilm of up to 84% for A. xylosoxidans CF2-b (p < 0.001) and as low as 6%
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(p = 0.0084) for In A. xylosoxidans LMG 1863T (Figure 4f). The effect of alginate lyase was restricted to
A. insuavis CF4-b, where a reduction in attached biofilm of 52% (p = 0.0044) was observed (Figure 4d).
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Figure 4. Enzymatic treatment both reduced and increased Achromobacter biofilm formation and caused
biofilm dispersal. Enzymatic treatment during biofilm formation (a–c, prevention) and enzymatic
treatment of 24 h old biofilms (d–f, dispersal) in A. xylosoxidans LMG 1863T, A. xylosoxidans CF2-b and
A. insuavis CF4-b. Biofilms were subjected to treatment with alginate lyase (a and d), DNase (b and e)
and subtilisin (c and f). 0: untreated, 1: low concentration of enzyme (50 µg/mL), 2: high concentration
of enzyme (200 g/mL) * Statistically significant reduction compared to untreated. ** Statistically
significant increase compared to untreated. A p-value < 0.05 was considered statistically significant.
3.5. Increased Antimicrobial Tolerance of Bacteria Embedded i iofil
Biofilm formation greatly increases t t f antibiotics n eded to eradicate bacteria.
Antimicrobial susceptibility t as performed on isolates A. xylosoxidans LMG 1863T,
A. xidans CF2-b and A. insuavis CF4-b in order to test how the biofilm mode of growth affected
the efficacy of antimicrobials. Tolerance to the tested antimicrobials increase dramatically for all
isolates when grown as biofilm (MBE ) hen co ared to planktonic cultures (MBC) (Table 2).
Generally, MBEC was between eight to 1000 fold higher than BC. Colistin had the greatest effect
on biofilm eradication, with an MBEC of 128 µg/mL in all isolates and an increase of only eight to
sixteen times MBC. The most pronounced increase in MBEC was found for piperacillin/tazobactam,
greatest in A. insuavis CF4-b, with an MBEC of 2048 µg/mL and an increase of 1000 times MBC.
We found no difference in MBEC between the two clinical isolates for colistin, piperacillin/tazobactam
and tobramycin, but the MBEC value for ceftazidime was four times higher in A. xylosoxidans CF2-b
compared to A. insuavis CF4-b. Antimicrobial tolerance increased in all isolates when was grown as
biofilms, and the amount of antimicrobials needed to fully eradicate the biofilms was up to 1000 fold
higher that for planktonic bacteria. Increased antimicrobial tolerance is likely to be the cause of many
unsuccessful eradication attempts in chronically infected cystic fibrosis patients.
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Table 2. Antimicrobial susceptibility of A. xylosoxidans LMG 1863T, A. xylosoxidans CF2-b and
A. insuavis CF4-b.
A. xylosoxidans LMG 1863T A. xylosoxidans CF2-b A. insuavis CF4-b
Antibiotic (µg/mL) MIC MBC MBEC MIC MBC MBEC MIC MBC MBEC
Piperacillin/tazobactam 1 8 1024 1 8 2048 1 2 2048
+ DNase I (200 µg/mL) - - 1024 - - 2048 - - 512
+ Subtilisin (200 µg/mL) - - 1024 - - 2048 - - 512
+ Alginate lyase (200 µg/mL) - - 1024 - - 2048 - - 2048
Ceftazidime 8 16 2048 8 8 2048 4 8 512
+ DNase I (200 µg/mL) - - 2048 - - 2048 - - 512
+ Subtilisin (200 µg/mL) - - 2048 - - 2048 - - 512
+ Alginate lyase (200 µg/mL) - - 2048 - - 2048 - - 512
Tobramycin >256 1024 1024 48 128 1024 24 64 1024
+ DNase I (200 µg/mL) - - 1024 - - 1024 - - 1024
+ Subtilisin (200 µg/mL) - - 1024 - - 1024 - - 1024
+ Alginate lyase (200 µg/mL) - - 1024 - - 1024 - - 1024
Colistin 4 8 128 4 8 128 4 16 128
+ DNase I (200 µg/mL) - - 128 - - 32 - - 64
+ Subtilisin (200 µg/mL) - - 64 - - 32 - - 64
+ Alginate lyase (200 µg/mL) - - 128 - - 128 - - 128
-, not tested.
Because enzyme treatment could partially disperse biofilms, we investigated if treatment with
subtilisin or DNase simultaneously with antibiotics would lead to a higher susceptibility to either
colistin or piperacillin. While the MBEC for piperacillin remained unchanged for 2 of the 3 isolates,
enzyme treatment did affect the MBEC for colistin in most cases (Table 2). Of the two enzymes
tested, subtilisin appeared to be most effective, as subtilisin treatment reduced the MBEC for colistin
for all 3 strains by 50%–75%, whereas DNase treatment led to a 50% reduction in the MBEC for
2 of the 3 strains. Enzymatic treatment did not reduce the MBEC of ceftazidime or tobramycin,
nor did enzymatic treatment with alginate lyase reduce the MBEC for any of the tested antibiotics.
Treatment with DNase or subtilisin partially dispersed the biofilm and reduced the tolerance to colistin
or piperacillin, paving the way for further research into using dispersal mechanisms to improve
treatment strategies.
4. Discussion
Biofilm formation is an important aspect of establishing and maintaining chronic infections
within the lungs of cystic fibrosis patients. Achromobacter xylosoxidans has the capacity to form biofilm
in vitro, yet little is known about its ability to form biofilm in vivo or of the structure, composition and
spatial distribution of Achromobacter biofilms within the CF lung. In the present study, we quantified
the amount of attached biofilm formed by clinical isolates of Achromobacter from CF patients and
characterized important aspects of biofilm formation in selected isolates.
The quantification of biofilm formation in different Achromobacter isolates revealed no inter-species
variation but rather a development over time after establishment of Achromobacter in the lung of
a given CF patient. Generally, isolates obtained after 1–4 years of chronic infection have reduced
capability to form attached biofilm in comparison with the initial isolate obtained from the same
patient. The reduction in biofilm formation was not caused by reduced in vitro growth rates in
later isolates, as has been seen in P. aeruginosa, where reduced biofilm formation was reflected
in lower growth rates [32]. Thus, the reduced formation of attached biofilm may result from
within-host adaptation to the CF lung [33]. A recent study [34] showed induction of aggregate
formation and increased hydrophobicity in P. aeruginosa in the presence of anti-Pseudomonas antibodies,
thereby increasing phagocytic clearance. Thus, it is possible that isolates that produce less attached
biofilm when obtained after years of chronic infection may have an altered morphotype where
aggregate formation is induced as a consequence of adaptive host mechanisms.
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Biofilms are classically defined as structured bacterial communities attached to a surface and
encased in a self-produced matrix [13]. However, surface attachment as a crucial part of biofilm
formation has since been challenged, and it was later proposed to include non-attached aggregates
in the biofilm definition [14]. In this study, we visualized in vitro biofilm growth, revealing distinctly
different biofilm morphotypes between selected Achromobacter isolates. A. xylosoxidans LMG 1863T and
A. xylosoxidans CF2-b both produced surface attached biofilms comprised of spherical aggregates of
approximately 5–10 µm in diameter (Figure 2a,b). A mesh-like structure of extracellular DNA similar
to previous findings in P. aeruginosa [27] was seen with A. xylosoxidans CF2-b when grown under
continuous flow, suggesting that eDNA may play a role in biofilm attachment in this isolate. In contrast,
A. insuavis CF4-b formed large non-attached or loosely attached biofilm-like aggregates when grown
under static conditions (Figure 2d), similar to previous reports of P. aeruginosa, Staphylococcus aureus
and some strains of A. xylosoxidans biofilms [11,14,35,36]. The biofilm aggregates appeared to be held
together by polysaccharides forming a peripheral shell around the bacterial cells. A. insuavis CF4-b did
not form attached biofilm under flow (Figure 2c), as un-attached bacteria were quickly removed from
the flow cells. Our results highlight the importance of critically evaluating the in vitro model used
for studying biofilm production by bacteria cultured from chronic infections, where the absence of
attachment to an abiotic surface may lead to falsely concluding that a clinical isolate is incapable of
forming biofilm.
In contrast to in vitro biofilm formation under high nutrient and oxygen availability, biofilms
within the CF airways form in dense mucus which may become oxygen depleted. In addition to oxygen
and nutrient availability, interactions with the host immune system, competition from other bacterial
species and antibiotic treatment may influence in vivo biofilm formation [37,38]. To investigate if our
in vitro observations represented the morphology of in vivo biofilms, we visualized Achromobacter sp.
in mucus collected from the patients from whom the isolates originated. Biofilm aggregates were
heterogeneously scattered throughout the sputum samples, and were much smaller than the aggregates
formed in vitro. The aggregates were 5–10 µm in diameter in sputum collected patient CF2 (Figure 4a),
whereas most aggregates in sputum from patient CF4 were up to approximately 40 µm in diameter
(Figure 4b). The aggregate morphology is consistent with our in vitro observations and with previous
findings showing biofilm-like aggregate structures in sputum from CF patients using Gram-stain [12].
In a review focusing on in vivo biofilms [38], two main differences in biofilm morphology between
in vitro and in vivo biofilms in chronic infections was pointed out. Firstly, the mushroom structure
typical for P. aeruginosa when grown in flow cells is not observed in vivo and secondly, the size of
biofilm aggregates is generally smaller in vivo. In accordance with this, Achromobacter aggregates
visualized in sputum were generally smaller than observed in vitro.
The biofilm phenotype is characterized by sessile bacteria with lowered metabolic activity
encased in an extracellular matrix [13]. These characteristics render biofilms highly tolerant towards
antimicrobials and shield the bacteria from the host immune system. Expectedly, we found an
increase in antimicrobial tolerance when Achromobacter was grown as biofilms, and the amount of
antibiotics needed to fully eradicate the biofilm was up to 1000 times higher than for planktonic cultures
(Table 2). Colistin is commonly used for treatment of cystic fibrosis. It targets the cells in the inner,
dormant part of the biofilm [39]. It can be administered as aerosolized antimicrobial inhalation therapy,
thereby achieving high local concentrations in sputum [40]. Nebulized colistin is used in Danish
CF centers and has been shown to prevent or postpone the development of chronic infection with
Achromobacter [41] and P. aeruginosa [42]. A recent study tested the effect of high-dose antimicrobials
on biofilm growth on three Achromobacter species from cystic fibrosis patients. The study showed that
levofloxacin and tobramycin had the greatest overall efficacy [19]. In this study, we found that colistin
had the lowest MBEC (128 µg/mL) of the tested antimicrobials (Table 2). This may be due to varying
antimicrobial resistance caused by differences in treatment schemes at the local cystic fibrosis centers,
as well as variation in in vitro growth conditions.
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Despite aggressive antimicrobial therapy, attempts to eradicate chronic infections in cystic fibrosis
patients are often unsuccessful. Attention has therefore turned to disrupting the biofilm matrix with
the intent to increase the penetration of antimicrobials into the biofilm and to disperse bacteria from
within the biofilm, rendering them susceptible to treatment. Since 1994, inhalation therapy using
human recombinant DNase has been used in treatment of cystic fibrosis patients, reducing the viscosity
of the sputum [43,44] and disrupting eDNA accumulating in the lungs [45]. Today, daily DNase
inhalation with Pulmozyme™ (dorenase alfa) is standard treatment in Danish CF centers, where it
has been proved beneficial to patients both with and without chronic pulmonary infection, improving
lung function and reducing the demand for antimicrobials [46,47].
We show here that eDNA is also important for in vitro Achromobacter biofilm formation.
Something which is also true for numerous other Gram-positive and Gram-negative bacteria [48,49].
The ability of DNase to disperse biofilm usually disappears within the first 12–24, and our study
presents the first example of DNase-mediated biofilm dispersal in mature (24 h old) Achromobacter
biofilms (Figure 4). Until the biofilm reaches a certain age, DNA has been shown to disperse biofilm in
other species [50,51]. It is not known whether this age-dependency applies to Achromobacter biofilms.
DNase I and subtilisin were able to disperse biofilms of all three isolates, whereas alginate lyase
only caused dispersal in A. insuavis CF4-b. The presence of enzymes from inoculation of the strain
during 24 h of biofilm development did in most cases reduce the generation of biofilm but could not
completely inhibit the biofilm formation (Figure 4a–c). Likewise, challenging the matrix of a mature
(24 h) biofilm with enzymes reduced biofilm biomass but did not eradicate the biofilm (Figure 4d–f).
However, our in vitro results suggests that combining antibiotic and enzymatic treatment has the
potential to help combatting Achromobacter biofilms in vivo by reducing the amount of antibiotics
needed to eradicate the biofilm.
Polysaccharides, such as alginate, are also an important component of the biofilm matrix,
and enzymatic treatment with alginate lyase has thus been shown to cause dispersal of
Pseudomonas aeruginosa [52], whereas enzymatic treatment with DNase I and proteinase impair biofilm
formation and cause dispersal in Listeria monocytogenes [53]. Even though an effect of alginate lyase was
shown on biofilm formation (A. xylosoxidans CF2-b and A. insuavis CF4-b) and dispersal (A. insuavis
CF4-b only) (Figure 4), no reduction in MBEC could be measured (Table 2). The alginate biosynthesis
protein AlgJ is present in the genome of A. xylosoxidans CF2b, however, as it is still not fully elucidated
whether all Achromobacter sp. produce alginate as part of the extracellular matrix, or whether a different
exopolysaccharide may be partially degraded by alginate lyase, other polysaccharide lyases might be
more effective in combination with antimicrobial treatment.
The fact that treatment with DNase I or subtilisin reduced the MBEC of colistin and that enzyme
treatment with DNase I, alginate lyase or subtilisin all showed a reduction in biofilm biomass
in Achromobacter biofilms paves the way for further research into using dispersal mechanisms,
possibly targeting several matrix components, to improve antimicrobial treatment strategies in
chronic Achromobacter infections in cystic fibrosis patients. A better understanding of the capacity of
Achromobacter to form biofilm may help improve diagnosis and treatment strategies of Achromobacter
in cystic fibrosis patients. A previous study [21] investigated SNP’s in whole-genome sequences of
CF1–CF5. It was apparent from this study that isolates CF2 and CF4 had not accumulated large
amounts of mutations (CF2 = 29 and CF4 = 17) when compared to the number of SNP’s found in CF5
(CF5 = 224) even though we found significant variation in biofilm formation at the isolate level in CF2
as well as CF5. We therefore hypothesize that changes in isolates from primary and chronic infections
may be caused by altered expression of genes related to biofilm formation rather than mutations at the
DNA level. Targets for parallel selection in P. aeruginosa biofilms include genes involved in type IV
pilus motility, flagellar motility, biofilm formation, metabolism and regulation [54] Likely these genes
will also be of interest when studying evolution of Achromobacter biofilms. Further studies elucidating
the genetic mechanisms involved in Achromobacter biofilm formation may provide valuable insight
into understanding the underlying mechanisms involved in biofilm formation and persistence in
chronic infections.
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